Different distribution of 62Cu ATSM and 18F-FDG in head and neck cancers

Clinical Nuclear Medicine

Volumn 37, Issue 3, 2012, Pages 252-257

  Kositwattanarerk, Arpakorn ^a   Oh, Myungmi ^a   Kudo, Takashi ^a   Kiyono, Yasushi ^a   Mori, Tetsuya ^a   Kimura, Yuichi ^a   Maruyama, Rikiya ^a   Fujibayashi, Yasuhisa ^a   Fujieda, Shigeharu ^a   Okazawa, Hidehiko ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Cu ATSM; FDG; Head and neck cancer; Hypoxic tissue; Spatial mismatch

Indexed keywords

COPPER 62; DIACETYL BIS(N4 METHLYTHIOSEMICARBAZONE) CU 62; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG TUMOR LEVEL; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HYPOXEMIA; MALE; RADIOISOTOPE DISTRIBUTION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; BIOPSY; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; THIOSEMICARBAZONES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84857197507     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31823eaadb     Document Type: Article

References (37)

1. Rockwell S, Dobrucki IT, Kim EY, et al. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med. 2009;9:442-458.
2. Adam MF, Gabalski EC, Bloch DA, et al. Tissue oxygen distribution in head and neck cancer patients. Head Neck. 1999;21:146-153. (Pubitemid 29096102)
3. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77:18-24. (Pubitemid 41503384)
4. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285-289. (Pubitemid 27318643)
5. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988;14:831-838.
6. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 2000;57:39-43.
7. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003;195:1-16. (Pubitemid 36603331)
8. 18F]-fluoroarabinofuranosyl)-2- nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging. 2009;36:1565-1573.
9. 18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34:1566-1575. (Pubitemid 47476913)
10. 18F]fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643-1652. (Pubitemid 33131323)
11. Lehtio K, Eskola O, Viljanen T, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:971-982. (Pubitemid 38834289)
12. Komar G, Seppanen M, Eskola O, et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med. 2008;49:1944-1951.
13. Fujibayashi Y, Cutler CS, Anderson CJ, et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol. 1999;26:117-121. (Pubitemid 29030531)
14. Takahashi N, Fujibayashi Y, Yonekura Y, et al. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia. Ann Nucl Med. 2001;15:293-296. (Pubitemid 32679229)
15. Lewis JS, Herrero P, Sharp TL, et al. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2002;43:1557-1569. (Pubitemid 35285882)
16. Ikawa M, Okazawa H, Arakawa K, et al. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion. 2009;9:144-148.
17. Isozaki M, Kiyono Y, Arai Y, et al. Feasibility of 62Cu-ATSM PET for evaluation of brain ischemia and misery perfusion in patients with cerebrovascular disease. Eur J Nucl Med Mol Imaging. 2011;31:1075-1082.
18. Takahashi N, Fujibayashi Y, Yonekura Y, et al. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med. 2000;14:323-328.
19. 64Cu(II)-diacetyl- bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47:989-998. (Pubitemid 46939952)
20. 64Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008;35:713-720.
21. Dearling JLJ, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol. 2010;37:237-243.
22. 60Cu-labeled diacetyl-bis(N4- methylthiosemicarbazone). J Nucl Med. 2008;49:201-205. (Pubitemid 351225657)
23. 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum. 2008;51:1641-1648.
24. 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844-850. (Pubitemid 36734203)
25. 18F-FDG in lung cancer. J Nucl Med. 2009;50:1948-1953.
26. Fujibayashi Y, Taniuchi H, Yonekura Y, et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160. (Pubitemid 27339632)
27. DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole body PET scanner. J Nucl Med. 1994;35:1398-1406. (Pubitemid 24243158)
28. Kamibayashi T, Tsuchida T, Demura Y, et al. Reproducibility of semiquantitative parameters in FDG-PET using two different PET scanners: influence of attenuation correction method and examination interval. Mol Imaging Biol. 2008;10:162-166.
29. 18F]fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: Consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys. 2011;79: 747-755.
30. 18F-FDG PET in patients with head and neck squamous cell cancer. Am J Roentgenol. 2009; 192:W156-W160.
31. Kubicek GJ, Champ C, Fogh S, et al. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol. 2010; 2:19.
32. 18Ffluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115:3196-3203.
33. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
34. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245-2252. (Pubitemid 38445681)
35. 18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol. 2006;80:151-156. (Pubitemid 44301544)
36. 18F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol. 2004;180:616-622. (Pubitemid 39361958)
37. + highly tumorigenic cells and metastatic ability of mouse colon carcinoma. Nucl Med Biol. 2011;38:151-157.